BWXT Announces Availability of FDA-Approved Indium In-111 Oxyquinoline Solution

 (LYNCHBURG, Va. – September 26, 2019) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT ITG Canada, Inc., having received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application for its generic version of Indium In-111 Oxyquinoline Solution, is now making the product available for sale in […]

Join the BWXT NEC Toronto Community Liaison Committee!

Local citizens and community organizations are invited to apply to the BWXT Nuclear Energy Canada (BWXT NEC) Community Liaison Committee (CLC). The deadline to apply is December 13, 2019 and new members will be notified in January 2020. The CLC was established in 2013 and its purpose is to create a forum for the exchange of information […]

BWX Technologies Reports Second Quarter 2019 Results With Solid Revenue and EPS Growth

Lynchburg, VA – August 5, 2019 – BWX Technologies, Inc. (NYSE: BWXT) (“BWXT”, “we”, “us” or the “Company”) reported second quarter 2019 revenue of $471 million, a 7.4% increase compared with $439 million in the second quarter of 2018.  GAAP net income for the second quarter 2019 was $58.9 million, or $0.62 per diluted share, compared […]

BWXT Names Leland D. Melvin to Board of Directors

(LYNCHBURG, Va. – June 18, 2019) – BWX Technologies, Inc. (NYSE:BWXT) announced today that Leland D. Melvin has been appointed to its board of directors.  Melvin spent more than 24 years with NASA as an astronaut, research engineer and administrator. He served twice on board the space shuttle Atlantis as a mission specialist to support […]

This Website Uses Cookies.

We use cookies to give you the best user experience. No personal information is collected in this process.